Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Empagliflozin in T2DM with High BMI
NCT07311551Phase 4Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Empagliflozin (2 arms). Primary endpoints: Glycated Hemoglobin at 6 months and Body Weight at 6 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07311551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311551.